Friday 16 October 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.99
0.00
0.00%
Follow LRMR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(78.24%) | (132.59%) | (109.83%) | (138.41%) | |
| (64.96%) | (95.75%) | (87.67%) | (108.53%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(95.09%) | (212.81%) | (105.21%) | (134.57%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.24) | (1.55) | (1.46) | (1.50) | |
Free Cash Flow |
(96.76) | (113.29) | (131.27) | (156.10) | |
Capital Expenditures |
(0.27) | (0.09) | — | (0.17) | |
| Other line items | |||||
Cash ROIC |
(30.77%) | (52.71%) | (36.63%) | (55.03%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.73 | 0.68 | 0.79 | 0.91 | |
Depreciation/Fixed assets |
(3.36) | (2.17) | (1.25) | (0.95) | |
Capex/Depreciation |
0.11 | 0.07 | 0.00 | 0.28 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.23) | (1.55) | (1.46) | (1.50) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates